Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Rating of “Hold” from Analysts

Posted by George Bondi on Jul 17th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) has been assigned a consensus rating of “Hold” from the seven brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $3.75.

A number of equities research analysts have recently weighed in on the company. Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th.

Read Our Latest Stock Report on Werewolf Therapeutics

Insider Transactions at Werewolf Therapeutics

In other news, Director Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $0.70, for a total value of $214,018.70. Following the completion of the transaction, the director directly owned 1,273,008 shares of the company’s stock, valued at approximately $891,105.60. The trade was a 19.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $0.35, for a total transaction of $145,918.85. Following the sale, the insider directly owned 303,719 shares of the company’s stock, valued at approximately $106,301.65. This represents a 57.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 4,067,237 shares of company stock worth $2,070,189. Insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors have recently made changes to their positions in HOWL. Susquehanna International Group LLP lifted its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares during the last quarter. Vontobel Holding Ltd. increased its position in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares during the period. Regal Investment Advisors LLC lifted its stake in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after buying an additional 25,389 shares during the last quarter. Bank of America Corp DE lifted its stake in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at $48,000. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $0.37 on Friday. The firm has a market cap of $17.88 million, a PE ratio of -0.30 and a beta of 0.30. The firm’s 50-day simple moving average is $0.41 and its 200-day simple moving average is $0.62. Werewolf Therapeutics has a 1 year low of $0.27 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. On average, equities analysts predict that Werewolf Therapeutics will post -1.08 earnings per share for the current year.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.

Analyst Recommendations for Werewolf Therapeutics (NASDAQ:HOWL)

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.